Adjuvant Pembrolizumab (NSCLC), Elacestrant, & Pirtobrutinib
OncoPharm
00:00
Elacestrant Efficacy in ESR1-Mutant Subgroup
John reports PFS HR 0.55 in ESR1-mutant patients, six- and 12-month PFS rates, and benefit magnitude versus physician's choice.
Play episode from 09:14
Transcript
